RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Core Insights - The first registry-eligible patient procedure in the PanTheR Post-Marketing Registry Study has been successfully completed at the University of Vermont Cancer Center, marking a significant milestone for RenovoRx and its RenovoCath device [1][2][3] - Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the University of Vermont Cancer Center as participating clinical sites in the PanTheR study, which aims to gather expanded safety and performance data on RenovoCath [2][3] - The PanTheR study is designed to evaluate the long-term safety and survival outcomes for patients with solid tumors treated using RenovoCath, capturing real-world data that may inform future clinical trial designs [5][8] Company Overview - RenovoRx, Inc. is a life sciences company focused on developing innovative targeted oncology therapies and commercializing the RenovoCath device, which is FDA-cleared for targeted drug delivery [7][8] - The RenovoCath device utilizes a patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, aiming to improve therapeutic delivery while minimizing toxicities compared to systemic intravenous therapy [8][9] - RenovoRx is also evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath, in the ongoing Phase III TIGeR-PaC trial [9][10] Study Details - The PanTheR study is a multi-center, post-marketing observational registry study that will collect data on the long-term use and performance of RenovoCath after its FDA clearance [5] - The study aims to generate meaningful real-world data that can guide future treatment decisions for patients with difficult-to-treat cancers, potentially improving survival and quality of life outcomes [4][5] - Participating cancer centers will purchase RenovoCath devices from RenovoRx for use in the study, reinforcing the company's commitment to innovation and patient outcomes [5][11]